Bexagliflozin (Brenzavvy) Shortage Update: What Patients Need to Know in 2026

If you've been prescribed Brenzavvy (bexagliflozin) and can't find it at your pharmacy, you may be wondering: is there an actual shortage? The answer requires a little nuance — and understanding it will help you get your medication faster.

Is Brenzavvy in an FDA-Declared Shortage in 2026?

No. As of early 2026, bexagliflozin (Brenzavvy) is not listed on the FDA Drug Shortage Database. There is no manufacturing shortage, no supply chain disruption, and no FDA alert about Brenzavvy availability.

However, many patients across the country are reporting difficulty finding Brenzavvy at their local pharmacies. This is a real access problem — it's just not a traditional drug shortage.

What Is Causing Brenzavvy Access Problems?

The difficulty accessing Brenzavvy stems from how TheracosBio chose to launch and distribute it:

Direct-to-consumer model: Brenzavvy launched in July 2023 exclusively through Mark Cuban's Cost Plus Drugs. It was not distributed through traditional pharmaceutical wholesalers that supply chain pharmacies.

Gradual expansion: By late 2023, distribution expanded to DiRx Pharmacy ($47.75/month) and the IPC network of independent pharmacies. Publix pharmacies also began stocking Brenzavvy in select locations.

No major chain presence: CVS, Walgreens, Rite Aid, and most grocery store pharmacies do not currently stock Brenzavvy due to low prescription volumes and limited wholesale availability.

Insurance formulary exclusions: Most Medicare Part D plans and commercial formularies do not include Brenzavvy, reducing both patient demand and pharmacy incentive to stock it.

Brenzavvy Availability Timeline: 2023–2026

January 2023: FDA approval. Brenzavvy becomes the 5th SGLT2 inhibitor approved in the US.

July 2023: Commercial launch via Cost Plus Drugs at $49.85/month.

December 2023: Distribution expands to DiRx Pharmacy ($47.75/month).

2024: IPC partnership adds 7,000+ independent pharmacies. Publix begins carrying in select locations. Some PBMs, including Scripius, add Brenzavvy as a preferred SGLT2 agent.

2025–2026: Continued expansion through additional partner pharmacies. Still not at most chain pharmacies. FDA confirms no drug shortage.

What Should Patients Do If They Can't Find Brenzavvy?

The key is knowing where to look. Here are your best options in order:

Use medfinder — medfinder.com calls pharmacies in your area to check which ones can fill your prescription. No hold music, no guessing.

Order online — Cost Plus Drugs ($49.85/month) and DiRx ($47.75/month) ship nationally. Have your doctor e-prescribe directly.

Try an independent pharmacy — IPC-member independent pharmacies can order Brenzavvy. Call your local independent pharmacy and ask.

Check Publix — If you're in the southeastern US, Publix pharmacy locations may have it in stock.

Ask your doctor about alternatives — If all else fails, other SGLT2 inhibitors work via the same mechanism and are widely available.

Will Brenzavvy Become More Widely Available?

The outlook is improving. TheracosBio has been steadily expanding its distribution network, and some PBMs have started preferring Brenzavvy over higher-cost SGLT2 inhibitors. As prescriptions grow, demand at chain pharmacies may eventually prompt them to stock it. For now, the online and independent pharmacy network is the most reliable channel.

Should I Be Concerned About Brenzavvy Supply Stability?

No. TheracosBio is a commercially focused company, and Brenzavvy is their primary product. There are no signs of manufacturing instability. In August 2024, TheracosBio confirmed that Brenzavvy remains the lowest-priced SGLT2 inhibitor nationwide, available through leading online and independent pharmacies at $50/month or less.